Skip to main content
Premium Trial:

Request an Annual Quote

Count Me In, Genome Medical Team up on Genetic Services for Rare Cancer Research Projects

NEW YORK – Count Me In, a nonprofit cancer research platform led by the Broad Institute, and telehealth provider Genome Medical said Thursday that they have partnered to offer genetic services to patients participating in two rare cancer research projects.

Financial terms of the deal were not disclosed.

Qualifying participants in either project will be referred to Genome Medical for genetic counseling and will be offered optional clinical germline genetic testing, which could reveal actionable results.

The two projects aim to accelerate and improve the understanding of leiomyosarcoma and osteosarcoma, which are rare cancers with limited treatments options. Count Me In, launched in 2018, is building specific datasets for both cancer types by engaging with patient communities, collecting samples, performing tumor-normal genomic sequencing, and gathering clinical information. De-identified data are shared with the biomedical research community.

"[T]he inclusion of genetic services provides the research community with needed information about the patients, as well as providing the patients with clinical information they need to make decisions about their health," Genome Medical CEO Jill Davies said in a statement.

"By integrating clinical genetic data with our research, we can better understand the genetic underpinnings of rare cancers like leiomyosarcoma and osteosarcoma, and ultimately accelerate the development of more targeted discoveries for these challenging diseases," Katie Janeway, principal investigator for the two projects, added.